曲妥珠单抗与帕妥珠单抗双靶向治疗人类表皮生长因子受体2阳性乳腺癌患者的效果及对血清肿瘤标志物水平的影响  

Effect of and Its Effect on Serum Tumor Marker Levels on Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer with Trastuzumab and Pertuzumab

作　　者：刘剑峰 王显臣 代广全 LIU Jianfeng;WANG Xianchen;DAI Guangquan(Department of Galactophore,Qingdao University Affiliated Weihai Municipal Second Hospital,Weihai,Shandong 264200,China)

机构地区：[1]青岛大学附属威海市立第二医院乳腺科,山东威海264200

出　　处：《中国医药指南》2025年第8期61-63,共3页Guide of China Medicine

摘　　要：目的 探讨人类表皮生长因子受体2(HER2)阳性乳腺癌患者实施双靶向治疗(曲妥珠单抗与帕妥珠单抗)的效果及对血清肿瘤标准物抑制情况。方法 选取60例2021年1月至2024年4月青岛大学附属威海市立第二医院乳腺科治疗的HER2阳性乳腺癌患者,以治疗方案差异为依据分作两组,30例接受曲妥珠单抗治疗者纳入对照组,30例行双靶向治疗(曲妥珠单抗与帕妥珠单抗)者纳入观察组,比较两组治疗效果、血清肿瘤标志物抑制情况[癌胚抗原(CEA)、糖类抗原15-3(CA15-3)]及不良反应发生情况。结果 观察组总有效率是96.67%,比对照组的76.67%高(P <0.05)。治疗后,两组CEA、CA15-3水平均降低,且组间对比观察组更低(P <0.05)。两组不良反应总发生率比较,差异无统计学意义(P> 0.05)。结论 在HER2阳性乳腺癌治疗中,双靶向治疗(曲妥珠单抗与帕妥珠单抗)可促进临床疗效进一步提升,使血清肿瘤标志物得到有效抑制,且安全性理想。Objective To investigate the effect of dual targeted therapy(trastuzumab and patuzumab)and the inhibition of serum tumor standard in breast cancer patients with positive human epidermal growth factor receptor 2(HER2).Methods A total of 60 patients with HER2-positive breast cancer treated at the Department of Breast Surgery,Weihai Second Municipal Hospital Affiliated to Qingdao University from January 2021 to April 2024 were selected.Based on differences in treatment regimens,they were divided into two groups:30 patients receiving trastuzumab treatment were assigned to the control group,and 30 patients receiving dual-target therapy(trastuzumab and pertuzumab)were assigned to the observation group.The treatment efficacy,suppression of serum tumor markers[carcinoembryonic antigen(CEA)and carbohydrate antigen 15-3(CA15-3)],and the incidence of adverse reactions were compared between the two groups.Results The total effective rate in the observation group was 96.67%,which was higher than that in the control group(76.67%)(P<0.05).After treatment,the levels of CEA and CA15-3 decreased in both groups,and the observation group showed lower levels compared to the control group(P<0.05).There was no statistically significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusions In the treatment of HER2 positive breast cancer,double targeted therapy(trastuzumab and patuzumab)can further improve the clinical efficacy,effectively inhibit serum tumor markers,and has ideal safety.

关 键 词：乳腺癌 HER2阳性 曲妥珠单抗 帕妥珠单抗 靶向治疗 肿瘤标志物 

分 类 号：R737.9[医药卫生—肿瘤]